



## Digital Health Technologies as an Adjunct to Medication Assisted Therapy for Opioid Use Disorder: Effectiveness and Value

Wednesday • November 18, 2020 • 10am – 3pm CT

Virtual Event – Zoom Webinar

[https://us02web.zoom.us/webinar/register/WN\\_wD2vUU9jQfa\\_LqXEjaNRSQ](https://us02web.zoom.us/webinar/register/WN_wD2vUU9jQfa_LqXEjaNRSQ)

Time (CT)	Activity
10:00 am—10:20 am	<b>Meeting Convened and Opening Remarks</b> <i>Steven D. Pearson, MD, MSc, ICER</i>
10:20 am—10:40 am	<b>Presentation of the Clinical Evidence</b> <i>Jeffrey A. Tice, MD, University of California, San Francisco</i>
10:40 am – 11:10 am	<b>Presentation of the Economic Model</b> <i>Melanie Whittington, PhD, MS, ICER</i>
11:10 am – 11:40 am	<b>Public Comments and Discussion</b>
11:40 am—12:00 pm	<b>Break</b>
12:00 pm—12:50 pm	<b>Midwest CEPAC Deliberation and Vote</b>
12:50 pm—1:30 pm	<b>Lunch</b>
1:30 pm—2:30 pm	<b>Policy Roundtable</b>
2:30 pm—3:00 pm	<b>Reflections from Midwest CEPAC and Closing Remarks</b>
3:00 pm	<b>Meeting Adjourned</b>

ICER Staff and Consultants	
<b>Pamela Bradt, MD, MPH,*</b> Chief Scientific Officer, ICER	<b>Maggie O’Grady, BS,*</b> Program Manager, ICER
<b>Jon Campbell, PhD, MS,*</b> Senior Vice President for Health Economics, ICER	<b>Steven D. Pearson, MD, MSc,*</b> President, ICER
<b>Rick Chapman, PhD, MS,*</b> Director of Health Economics, ICER	<b>Jeffrey A. Tice, MD,*</b> Professor of Medicine, University of California, San Francisco
<b>Noemi Fluetsch, MPH,*</b> Research Assistant, ICER	<b>Melanie Whittington, PhD, MS,*</b> Associate Director of Health Economics, ICER
<b>Maggie Houle, BS,*</b> Program and Event Coordinator, ICER	<b>Lorenzo Villa Zapata, PhD, PharmD,*</b> Post-doctoral fellow University of Colorado Anschutz Medical Center
<b>Nicholas Mendola, MPH,*</b> PhD Student University of Colorado Anschutz Medical Center	

\*No conflicts of interest to disclose, defined as individual health care stock ownership in any health plan or pharmaceutical, biotechnology, or medical device manufacturers, or any health care consultant income or honoraria from health plans or manufacturers.

### Participating Members of Midwest CEPAC

<b>Eric Armbrrecht, PhD (Chair),*</b> Associate Professor, Saint Louis Center for Health Outcomes Research, School of Medicine and College for Public Health and Social Justice	<b>Jill Johnson, PharmD,*</b> Professor, University of Arkansas for Medical Sciences
<b>Angela Brown, MPH,*</b> Chief Executive Officer, St. Louis Regional Health Commission	<b>Chris Jones, PhD*,</b> Network Director, Venture Investments, University of Vermont Health Network
<b>Donald Casey, MD, MPH, MBA,*</b> President, American College of Medical Quality	<b>Greg Low, RPh, PhD,*</b> Director, Massachusetts General Physicians Organization Pharmacy Quality and Utilization Program
<b>Greg Curfman, MD,*</b> Deputy Editor, JAMA	<b>Tim McBride, PhD,*</b> Co-Director, Center for Health Economics and Policy; Professor, Washington University in St. Louis
<b>Stacie Dusetzina, PhD,*</b> Associate Professor of Health Policy, Vanderbilt University School of Medicine	<b>Jeanne Ryer, MSc, EdD,*</b> Director of Delivery System and Payment Reform, University of New Hampshire Institute for Health Policy and Practice
<b>Megan Golden, JD,*</b> Co-Director, Mission: Cure	<b>Timothy Wilt, MD, MPH*,</b> Professor of Medicine; Director, Minnesota Evidence-based Synthesis Program, Minneapolis VA Center for Chronic Disease Outcomes Research
<b>Elbert Huang, MD, MPH,*</b> Professor of Medicine; Director, Center for Chronic Disease Research and Policy, University of Chicago	<b>Stuart Winston, DO,*</b> Physician Lead, Professional Enhancement Program, Integrated Health Associates

\*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Policy Roundtable Participant	Conflict of Interest
<b>Kelcey Blair, PharmD,</b> Vice President, Clinical Solutions at Express Scripts	Kelcey is a full-time employee of Express Scripts.
<b>Anita Ju,</b> Innovation Manager, Blue Shield of California	Anita is a full-time employee of Blue Shield of California.
<b>Miriam Komaromy, MD, FACP, DFASAM,</b> Medical Director, Grayken Center for Addiction, Boston Medical Center, Boston University	No financial conflicts of interest to disclose.
<b>Hans Morefield,</b> Chief Executive Officer, CHES Health	Hans is a full-time employee of CHES Health.
<b>Jake Nichols, PharmD, MBA,</b> President and Chief Executive Officer, Professional Recovery Associates	Jake Nichols was previously employed by Pear Therapeutics.
<b>Mike Pace, MBA,</b> Vice President and Global Head of Market Access, Value, and Evidence, Pear Therapeutics	Mike is a full-time employee of Pear Therapeutics.
<b>Kevin Roy, MBA,</b> Chief Public Policy Officer, Shatterproof	No financial conflicts of interest to disclose.
<b>Scott Steiger, MD, FACP, FASAM,</b> Associate Clinical Professor of Medicine and Psychiatry, University of California San Francisco	No financial conflicts of interest to disclose.